Data on Neogenix Oncology, Inc.’s Phase I Study of Novel Therapeutic Antibody NPC-1C (Ensituximab) to be Presented at American Society of Clinical Oncology’s 2011 Annual Meeting

Published: Jun 03, 2011

Neogenix Oncology announced today that researchers from Johns Hopkins University Hospital will be giving a poster presentation on the phase I study of ensituximab, a novel therapeutic antibody to treat pancreas and colorectal cancers. The presentation is scheduled at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting to be held June 3-7, 2011 at McCormick Place in Chicago, IL, USA.

Back to news